MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
*Portfolio Companies: MedVenture
NeuroPace, Inc. (NASDAQ: NPCE) -CCF*
Organization & Developments: NeuroPace
Parents
NeuroPace, Inc. (NASDAQ: NPCE) -CCF*
Children
*By responsive brain stimulation.
*External products, such as the programmer, a laptop computer with proprietary software that has a wand and telemetry interface enabling communication with an implanted RNS neurostimulator.
*In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical diso
*It offers responsive Neurostimulator system (RNS) for the treatment of medically refractory partial epilepsy.
*NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders
*Patients are currently being enrolled in a clinical trial of the company's Responsive Neurostimulator (RNS(TM)) system for treat
*RNS System in the treatment of idiopathic generalized epilepsy.
*The company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the
*The company’s RNS system consists of implantable components, including RNS neurostimulator that delivers a short train of electrical pulses to the brain, and depth leads and cortical strip leads
2021: Neuromodulation for Lennox-Gastaut Syndrome: Interview with Martha Morrell, M.D., CMO of NeuroPace
2021: The device is already approved in the treatment of drug-resistant focal epilepsy with no more than two epileptogenic foci
2022: Neuropace (NPCE) Investor Presentation - Slideshow_ seekingalpha.com
2024: NeuroPace, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: NeuroPace: Only For Those With Strong Nerves
2024: NeuroPace: Picking Up The Pace
2025: NeuroPace falls after setback in trial for neuromodulation system
2025: NeuroPace outlines 20%+ CAGR through 2027 as RNS business momentum accelerates
2025: NeuroPace Says Epilepsy Trial Meets Safety Goal, Misses Overall Efficacy Target
2025: NeuroPace, Inc. 2024 Q4 - Results - Earnings Call Presentation
Jumps
*Key People: NeuroPace
Finance & Acquisitions: NeuroPace